SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

SCHEDULE 13D

UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. 1)*

Tango Therapeutics, Inc.

(Name of Issuer)

Common Stock, \$0.001 par value (Class of Securities)

87583X109 (CUSIP Number)

Kevin Gillis
Third Rock Ventures, LLC
201 Brookline Ave, Suite 1401, Boston, MA 02215
(617) 585-2000
(Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)

August 30, 2024 (Date of Event Which Requires Filing of Statement on Schedule 13D)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of \$\$240.13d-1(e), 240.13d-1(g), checking the following box. \Box

* The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

CI	IS	D .	8	75	23	X	11	Q

(1)	Name of Reporting Persons:						
	Third Rock Ventures IV, L.P.						
(2)			priate Box if a Member of a Group (See Instructions):				
	(a) \square	(b) 🗵					
(3)	SEC Use	Only:					
(4)	Source of	Funds (See Instructions):				
	WC						
(5)		x if Dis	closure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):				
()							
(6)	Citizenshi	p or Pla	ice of Organization:				
	Delaware						
	Delaware	(7)	Sole Voting Power				
		(7)	Sole voting I ower				
NU	TUMBER OF 0						
	SHARES (8) Shared Voting Power						
	EFICIALLY	. ,					
	WNED BY EACH 17,001,475						
	PORTING	(9)	Sole Dispositive Power				
	ERSON						
,	WITH:	(10)					
		(10)	Shared Dispositive Power				
			17,001,475				
(11)	Aggregate	Amour	nt Beneficially Owned by Each Reporting Person:				
		_					
(12)	17,001,475						
(12)	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):						
(13)							
(1.4)	15.9%*						
(14)	Type of Reporting Person (See Instructions):						
	PN						

^{*} The percent of class was calculated based on 107,144,465 shares of common stock issued and outstanding as of August 1, 2024, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on August 7, 2024.

α	ISI	n.	o'	750	α	V/	1 (n
u	101	P	δ.	/ 7	^ 1		II.	19

(1)	Nama of I) an autiv	Darsona:				
(1)	Name of Reporting Persons:						
	Third Rock Ventures GP IV, L.P.						
(2)			oriate Box if a Member of a Group (See Instructions):				
	(a) □	(b) 🗵					
(3)	SEC Use Only:						
()							
(4)	Source of	Funds (See Instructions):				
	AF						
(5)		x if Dis	closure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):				
	_						
(6)	Citizanahi	n or Dia	ce of Organization:				
(6)	Citizensni	p or Pia	ice of Organization:				
	Delaware						
		(7)	Sole Voting Power				
NU	MBER OF		0				
S	SHARES (8) Shared Voting Power						
	EFICIALLY						
	OWNED BY EACH 17,001,475						
	PORTING	(9)	Sole Dispositive Power				
	ERSON WITH:		0				
	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	(10)	Shared Dispositive Power				
			17,001,475				
(11)	Aggregate	Amour	at Beneficially Owned by Each Reporting Person:				
, ,							
(12)	17,001,475						
(12)	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):						
(13)	Percent of	Class F	Represented by Amount in Row (11):				
	15.9%*						
(14)		eporting	Person (See Instructions):				
	PN						

^{*} The percent of class was calculated based on 107,144,465 shares of common stock issued and outstanding as of August 1, 2024, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on August 7, 2024.

CI	IS	D .	8	75	23	X	11	Q

(1)	Name of Reporting Persons:						
	TRV GP IV, LLC						
(2)			oriate Box if a Member of a Group (See Instructions):				
()	(a) 🗆	(b) ⊠					
(3)	SEC Use	Only:					
(4)	Source of	Funds (See Instructions):				
	AF						
(5)	Check Bo	x if Dis	closure of Legal Proceedings is Required Pursuant to Items 2(d) or 2(e):				
(6)		n or Pla	ce of Organization:				
(0)		p or r io	or organization.				
	Delaware						
		(7)	Sole Voting Power				
NUI	MBER OF		0				
	SHARES (8) Shared Voting Power						
	EFICIALLY /NED BY						
	EACH 17,001,473						
REI	PORTING	(9)	Sole Dispositive Power				
	ERSON WITH:		0				
	WIIII.	(10)	Shared Dispositive Power				
			17,001,475				
(11)	Aggregate	Amour	at Beneficially Owned by Each Reporting Person:				
(11)	1188108410	7 IIIIO GI	Denoticianly 6 whoa by Each Reporting Poison.				
	17,001,475						
(12)	Check Box if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):						
(13)							
	15.00/#						
(14)	15.9%* Type of Ro	enorting	Person (See Instructions):				
(11)	1 Type of reporting Leison (See Instructions).						
	00						

^{*} The percent of class was calculated based on 107,144,465 shares of common stock issued and outstanding as of August 1, 2024, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on August 7, 2024.

CUSIP: 87583X109

EXPLANATORY STATEMENT

This Amendment No. 1(this "Amendment") amends and supplements the Schedule 13D (the "Schedule 13D") filed by the Reporting Persons on August 19, 2021, with respect to the shares of common stock, \$0.001 par value per share ("Common Stock"), of Tango Therapeutics, Inc. (the "Company" or the "Issuer"). The transactions described in Item 5(c) resulted in a decrease of over one percent (1%) in the aggregate percentage ownership reported by the Reporting Persons in the Schedule 13D. Except as specifically provided herein, this Amendment does not modify any of the information previously reported in the Schedule 13D.

ITEM 5. INTEREST IN SECURITIES OF THE ISSUER

Item 5(a)-(c) is hereby amended and restated as follows:

(a) As of August 30, 2024, TRV IV had shared voting and dispositive power with respect to 17,001,475 shares of the Issuer's Common Stock, constituting approximately 15.9% of the Issuer's outstanding Common Stock.

As of August 30, 2024, Third Rock Ventures GP IV, L.P. ("**TRV GP IV**"), as the general partner of TRV IV may be deemed to have shared voting and dispositive power with respect to all 17,001,475 shares of the Issuer's Common Stock owned by TRV IV, constituting approximately 15.9% of the Issuer's outstanding Common Stock.

As of August 30, 2024, TRV GP IV, LLC ("**TRV GP IV LLC**," and collectively with TRV IV and TRV GP IV, the "**Reporting Persons**"), as the general partner of TRV GP IV may be deemed to have shared voting and dispositive power with respect to all 17,001,475 shares of the Issuer's Common Stock owned by TRV IV, constituting approximately 15.9% of the Issuer's outstanding Common Stock.

The percent of class was calculated based on 107,144,465 shares of common stock issued and outstanding as of August 1, 2024, as disclosed in the Issuer's 10-Q filed with the Securities and Exchange Commission on August 7, 2024.

(b)

Regarding the number of shares as to which such person has:

- (i) sole power to vote or to direct the vote: See line 7 of cover sheets
- (ii) shared power to vote or to direct the vote: See line 8 of cover sheets
- (iii) sole power to dispose or to direct the disposition: See line 9 of cover sheets.
- (iv) shared power to dispose or to direct the disposition: See line 10 of cover sheets
- (c) Except as set forth in the table below, no transactions in the Common Stock were effected by the Reporting Persons during the 60-day period ended August 30, 2024.

	Date	Amount of Securities	Price per Share	Where and How Effected
TRV IV	07/17/2024	550,171	\$ 9.7903*	Disposed in the Open Market
TRV IV	07/18/2024	191,490	\$ 9.8098	Disposed in the Open Market
TRV IV	07/22/2024	262,740	\$ 9.7819*	Disposed in the Open Market
TRV IV	07/23/2024	125,000	\$ 9.7868*	Disposed in the Open Market
TRV IV	07/24/2024	200,000	\$ 9.8158*	Disposed in the Open Market
TRV IV	07/25/2024	100,599	\$ 9.8686*	Disposed in the Open Market
TRV IV	07/26/2024	50,000	\$ 9.839*	Disposed in the Open Market
TRV IV	07/30/2024	95,000	\$ 9.8012*	Disposed in the Open Market
TRV IV	07/31/2024	100,000	\$ 9.9338*	Disposed in the Open Market
TRV IV	08/01/2024	40,000	\$ 9.8	Disposed in the Open Market
TRV IV	08/16/2024	135,000	\$ 9.7885*	Disposed in the Open Market
TRV IV	08/19/2024	150,000	\$10.0928*	Disposed in the Open Market
TRV IV	08/27/2024	25,000	\$11.5466*	Disposed in the Open Market
TRV IV	08/30/2024	175,000	\$11.5983	Disposed in the Open Market

^{*} The price reported is a weighted average price. These shares were sold in multiple transactions.

CUSIP: 87583X109

SIGNATURE

After reasonable inquiry and to the best of his knowledge and belief, the undersigned certifies that the information set forth in this Statement is true, complete and correct.

Dated: September 4, 2024

THIRD ROCK VENTURES IV, L.P.

By: THIRD ROCK VENTURES GP IV, L.P., General Partner

By: TRV GP IV, LLC, General Partner

By: /s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer

THIRD ROCK VENTURES GP IV, L.P.

By: TRV GP IV, LLC, General Partner

By: /s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer

TRV GP IV, LLC

By: /s/ Kevin Gillis
Kevin Gillis
Chief Operating Officer